News | February 22, 2023
Merck updates on Phase 3 MOVe-AHEAD trial evaluating Lagevrio
The safety profile of LAGEVRIO in this trial was generally consistent with that observed in previously reported clinical studies
The safety profile of LAGEVRIO in this trial was generally consistent with that observed in previously reported clinical studies
Agasta Software is engaged in research, development and commercialization of medical devices
Fluor is providing architectural and engineering services and procuring equipment for the new 275,000 square-foot manufacturing facility that will house two manufacturing lines to double manufacturing capability
FDA also accepts a separate supplemental application to extend prophylaxis with PREVYMIS to 200 days in certain HSCT recipients
The company has launched its new range of 25 allopathy ophthalmic products including GUERIMOD, GUERIPRED, BIMATO MST etc. for curing various diseases related to eyes
According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year
Qure.ai is scaling-up the integration of its AI-powered chest x-ray interpretation tool that can benefit early and easy detection of lung diseases including lung cancer.
Dr. Dietmar Berger, has agreed to take the leadership of the team ad interim
The Ministry of Ayush endeavour is to get entry level NABH certification for 12,500 Ayush Wellness Centers by the end of 2023
The Innovation Explorer database of GlobalData’s Disruptor Intelligence Center highlights the key company collaborations in pharma to advance AI-powered drug repurposing techniques.
Subscribe To Our Newsletter & Stay Updated
